

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**NOVEN PHARMACEUTICALS, INC.,  
Petitioner**

**v.**

**NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,  
Patent Owners**

---

***Inter Partes* Review No.: 2014-00550  
U.S. Patent No. 6,335,031**

**PETITIONER'S EXHIBIT LIST 2**

Pursuant to 37 C.F.R. §42.63(e), Petitioner Noven submits the following current exhibit list.

<b>Noven Exhibit No.</b>	<b>Description</b>
Ex. 1001	U.S. Patent No. 6,335,031, issued January 1, 2002
Ex. 1002	UK Patent Application GB 2,203,040 A, to Enz, published October 12, 1988 (“Enz”)
Ex. 1003	Handbook of Pharmaceutical Excipients, A. Wade and P. J. Weller (eds.) 1994, 2 <sup>nd</sup> Edition, The Pharmaceutical Press London (the “Handbook”)
Ex. 1004	Japanese Patent Application Publication No. JP 59-184121 to Sasaki et al., published October 19, 1984
Ex. 1005	Certified English Translation of Japanese Patent Application Publication No. JP 59-184121 to Sasaki et al. (“Sasaki”)
Ex. 1006	PCT Publication No. WO 95/024172 to Ebert et al, published September 14, 1995 (“Ebert”)
Ex. 1007	Carey & Sundberg, ADVANCED ORGANIC CHEMISTRY, Part A: Structure and Mechanism, 3rd Edition (Plenum Press, NY), pp.

	651-727 (1990)
Ex. 1008	U.S. Patent 4,948,807 (“Rosin”)
Ex. 1009	Elmalem et al. 1991, Neuropharmacology 30: 1059-1064 (“Elmalem”)
Ex. 1010	Declaration of Agis Kydonieus, Ph.D.
Ex. 1011	Declaration of Christian Schöneich, Ph.D.
Ex. 1012	“Safety/Tolerability Trial of SDZ ENA 713 in Patients with Probable Alzheimer’s Disease,” John J. Sramek et al., Life Sciences, Vol. 58, No. 15, pp. 1201-1207 (1996) (“Sramek”)
Ex. 1013	“New acetylcholinesterase inhibitor shows promise in largest Alzheimer’s trial to date,” Formulary, Vol. 32, Dec. 1997 (“Formulary Article”)
Ex. 1014	ICH Topic Q 1 A, Stability Testing Guidelines: Stability Testing of New Drug Substances and Products (CPMP/ICH/380/95)
Ex. 1015	Connors, Amidon, & Stella, Oxidation and Photolysis in Chemical Stability of Pharmaceuticals – A Handbook for Pharmacists (2nd Edition), John Wiley & Sons, NY (1986), pp. 82-114

Ex. 1016	Howard C. Ansel, Introduction to Pharmaceutical Dosage Forms, 4th Edition, Lea & Febiger, Philadelphia (1985), pp. 83-116
Ex. 1017	Ho-Leung Fung, Chapter 7 – Chemical Kinetics and Drug Stability in MODERN PHARMACEUTICS (G.S. Banker and C.T. Rhodes, eds.), Marcel Dekker, NY (1979), pp. 227-62
Ex. 1018	Miguel-Hidalgo, J., 2000, Current Opinion in CPNS Investigations Drugs, 2000 2(4):438-453
Ex. 1019	Boccardi G. et al. Photochemical Iron(III)-Mediated Autoxidation of Dextromethorphan. Chemical & Pharmaceutical Bulletin. Vol. 37, 308–310 (1989)
Ex. 1020	Bateman, L., Olefin Oxidation, Quarterly Review (1954) Vol. 8, pp. 147–167
Ex. 1021	Linnell, R.H., The Oxidation of Nicotine. I. Kinetics of the Liquid Phase Reaction Near Room Temperature. Tobacco Science, Vol. 4, pp. 89–91 (1960)
Ex. 1022	Resume/Curriculum Vitae of Agis Kydonieus, Ph.D.
Ex. 1023	Resume/Curriculum Vitae of Christian Schöneich, Ph.D.

Ex. 1024	U.S. Patent No. 5,602,176, issued Feb. 11, 1997
Ex. 1025	Redacted Copy of Bench Trial Transcript (Day 1). C.A. No. 13-527, D.I. 154 (D. Del).
Ex. 1026	Redacted Copy of Bench Trial Transcript (Day 2). C.A. No. 13-527, D.I. 155 (D. Del).
Ex. 1027	Redacted Copy of Bench Trial Transcript (Day 3). C.A. No. 13-527, D.I. 156 (D. Del).
Ex. 1028	U.S. Patent No. 5,061,480. [Not Filed]
Ex. 1029	Transcript of 1/13/2015 Deposition of Dr. Agis Kydonieus
Ex. 1030	Reserved
Ex. 1031	Reply Declaration of Agis Kydonieus
Ex. 1032	Reply Declaration of Christian Schoneich, Ph.D.
Ex. 1033	Internal Novartis memorandum written by Dr. Tiemessen. (N0272228-29.)
Ex. 1034	Internal Novartis e-mail communication from Dr. Tiemessen to O. Garinot. (N0272563.)
Ex. 1035	Meeting Minutes of the LTS-Sandoz (Novartis) Working Group.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.